Advertisement

Biochemical Analysis and Association of Butyrylcholinesterase SNPs rs3495 and rs1803274 with Substance Abuse Disorder

  • Sadaf Munir
  • Rabia HabibEmail author
  • Sliha Awan
  • Nazia Bibi
  • Arooj Tanveer
  • Sajida Batool
  • Syed M. NurulainEmail author
Article

Abstract

Addiction is a complex mental and behavioral disorder that changes the neurochemistry and physiology of the brain. Genetics also plays a significant role in the pathophysiology of addiction. Butyrylcholinesterase (BChE), a cholinergic enzyme, has been implicated in the metabolism of various drugs, including cocaine, and an association between single-nucleotide polymorphisms (SNPs) of the butyrylcholinesterase gene (BCHE) and neuronal disorders has been reported. We report here the first investigation to be conducted on the status of BChE activity and the potential association of two BCHE gene SNPs, rs3495 (c.*189G > A) and rs1803274 (c.1699G>A, p.Ala567Thr, K-variant), with addiction vulnerability in heroin, hashish and polydrug users. Seventy-five individuals with an addiction to heroin, hashish and/or polydrug use were recruited to this study. BChE levels in the plasma were determined by Ellman’s principle. SNPs were genotyped by standard procedures, followed by Sanger sequencing. Plasma BChE levels were found to be significantly higher (p ≤ 0.05) in addicts (mean ± standard error of the mean 0.031 ± 0.004 μmol/L/min; 95% confidence interval [CI] 0.024–0.038) than in non-addicts (controls) (0.014 ± 0.001 μmol/L/min; 95% CI 0.012–0.017). Statistical significant differences were also observed between the addicted cohorts. A statistically significant association for both SNPs (rs3495 and rs1803274) was not observed in addicted subjects tested in the dominant, recessive and allele genetic models, but trends of variations of the rs3495 risk G allele were noted. The authors conclude that BChE plays significant roles in addiction pathophysiology as increased BChE activity in blood samples obtained from the cohorts with addiction was evident. Further studies in this direction may provide novel approaches for the treatment of addiction, but studies with a larger sample size and different ethnic groups are warranted for broader conclusions to be drawn.

Keywords

Substance abuse Butyrylcholinesterase rs3495 rs1803274 Hashish Polydrug 

Notes

Acknowledgements

The authors acknowledge Mental Health and Care, Islamabad and Sehar Rehabilitation Center, Sargodha for facilitating the research.

Funding

The work was sponsored by CIIT research grant #16–20/CRGP/CIIT/IBD/16 to Dr. Syed M Nurulain.

Compliance with Ethical Standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards

Conflict of Interest

The authors declare no conflicts of interest and no financial interests.

Supplementary material

12031_2018_1251_MOESM1_ESM.pdf (276 kb)
Supplemental Table 1 (PDF 276 kb)

References

  1. Aeinehband S, Lindblom RPF, Al Nimer F, Vijayaraghavan S, Sandholm K, Khademi M, Olsson T, Nilsson B, Ekdahl KN, Darreh-Shori T, Piehl F (2015) Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis. PLoS One 10:e0122048CrossRefGoogle Scholar
  2. Ashani Y (2000) Prospective of human butyrylcholinesterase as a detoxifying antidote and potential regulator of controlled-release drugs. Drug Dev Res 50:298–308CrossRefGoogle Scholar
  3. Askalsky P, Kalapatapu RK, Foltin RW, Comer SD (2015) Butyrylcholinesterase levels and subjective effects of smoked cocaine in healthy cocaine users. Am J Drug Alcohol Abuse 41:161–165CrossRefGoogle Scholar
  4. Babaoglu MO, Ocal T, Bayar B, Kayaalp SO, Bozkurt A (2004) Frequency and enzyme activity of the butyrylcholinesterase K-variant in a Turkish population. Eur J Clin Pharmacol 59:875–877CrossRefGoogle Scholar
  5. Bartels CF, Van Der Spek AFL, La Du BN (1990) Two polymorphisms in the non-coding regions of the BCHE gene. Nucleic Acids Res 18:6171CrossRefGoogle Scholar
  6. Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T, La Du BN (1992) DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 50:1086–1103PubMedPubMedCentralGoogle Scholar
  7. Benyamin B, Middelberg RP, Lind PA, Valle AM, Gordon S, Nyholt DR, Medland SE, Henders AK, Heath AC, Madden PAF, Visscher PM, O’Connor DT, Montgomery GW, Martin NG, Whitfield JB (2011) GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors. Hum Mol Genet 20:4504–4514CrossRefGoogle Scholar
  8. Bono GF, Simão-Silva DP, Batistela MS, Josviak ND, Dias PFR, Nascimento GA, Souza RLR, Piovezan MR, Souza RKM, Furtado-Alle L (2015) Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer’s disease in a southern Brazilian population. Neurochem Int 81:57–62CrossRefGoogle Scholar
  9. Brook JS, Newcomb MD (1995) Childhood aggression and unconventionality: impact on later academic achievement, drug use, and workforce involvement. J Genet Psychol 156:393–410CrossRefGoogle Scholar
  10. Carmona GN, Baum I, Schindler CW, Goldberg SR, Jufer R, Cone E, Slaughter E, Belendiuk GW, Gorelick DA (1996) Plasma butyrylcholinesterase activity and cocaine half-life differ significantly in rhesus and squirrel monkeys. Life Sci 59:939–943CrossRefGoogle Scholar
  11. Carmona GN, Jufer RA, Goldberg SR, Gorelick DA, Greig NH, Yu QS, Cone EJ, Schindler CW (2000) Butyrylcholinesterase accelerates cocaine metabolism: in vitro and in vivo effects in nonhuman primates and humans. Drug Metab Dispos 28:367–371PubMedGoogle Scholar
  12. Chen VP, Gao Y, Geng L, Parks RJ, Pang YP, Brimijoin S (2015) Plasma butyrylcholinesterase regulates ghrelin to control aggression. Proc Natl Acad Sci USA 112:2251–2256CrossRefGoogle Scholar
  13. Cokugras AN (2003) Butyrylcholinesterase: structure and physiological importance. Turk J Biochem 28:54–61Google Scholar
  14. Darvesh S, MacKnight C, Rockwood K (2001) Butyrylcholinesterase and cognitive function. Int Psychogeriatr 13:461–464CrossRefGoogle Scholar
  15. Darvesh S, Hopkins DA, Geula C (2003) Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 4:131–138CrossRefGoogle Scholar
  16. Darvesh S, Leblanc AM, Macdonald IR, Reid GA, Bhan V, Macaulay RJ, Fisk JD (2010) Butyrylcholinesterase activity in multiple sclerosis neuropathology. Chem Biol Interact 187:425–431CrossRefGoogle Scholar
  17. de Oliveira J, Tureck LV, Santos WD, Saliba LF, Schenknecht CS, Scaraboto D, Souza RLR, Furtado-Alle L (2017) Effect of BCHE single nucleotide polymorphisms on lipid metabolism markers in women. Genet Mol Biol 40:408–414CrossRefGoogle Scholar
  18. Delacour H, Lushchekina S, Mabboux I, Bousquet A, Ceppa F, Schopfer LM, Lockridge O, Masson P (2014) Characterization of a novel BCHE “silent” allele: point mutation (p.Val204Asp) causes loss of activity and prolonged apnea with suxamethonium. PLoS One 9:e101552CrossRefGoogle Scholar
  19. Ellman GL, Courtney KD, Andres V, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95CrossRefGoogle Scholar
  20. Erzegovesi S, Bellodi L, Smeraldi E (1995) Serum cholinesterase in obsessive-compulsive disorder. Psychiatry Res 58:265–268CrossRefGoogle Scholar
  21. Fiocco AJ, Nair NPV, Schwartz G, Kin FNY, Joober R, Poirier J, Lupien SJ (2009) Influence of genetic polymorphisms in the apolipoprotein (APOE) and the butyrylcholinesterase (BCHE) gene on stress markers in older adults: a 3-year study. Neurobiol Aging 30:1001–1005CrossRefGoogle Scholar
  22. Garcia DF, Oliveira TG, Molfetta GA, Garcia LV, Ferreira CA, Marques AA, Silva WA (2011) Biochemical and genetic analysis of butyrylcholinesterase (BChE) in a family, due to prolonged neuromuscular blockade after the use of succinylcholine. Genet Mol Biol 34:40–44CrossRefGoogle Scholar
  23. Gatley SJ (1991) Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem Pharmacol 41:1249–1254CrossRefGoogle Scholar
  24. Giacobini E (2000) Cholinesterase inhibitors stabilize Alzheimer’s disease. Ann N Y Acad Sci 920:321–327CrossRefGoogle Scholar
  25. Gorelick DA (2008) Pharmacokinetic approaches to treatment of drug addiction. Expert Rev Clin Pharmacol 1:277–290CrossRefGoogle Scholar
  26. Guimarães LO, de Andrade FA, Bono GF, Setoguchi TE, Brandão MB, Chautard-Freire-Maia EA, dos Santos ICR, Picheth G, Faria AC, Réa RR, Souza RLR, Furtado-Alle L (2014) Gestational diabetes mellitus (GDM) decreases butyrylcholinesterase (BChE) activity and changes its relationship with lipids. Genet Mol Biol 37:1–6CrossRefGoogle Scholar
  27. Hosoi M, Hori K, Konishi K, Tani M, Tomioka H, Kitajima Y, Akashi N, Inamoto A, Minami S, Izuno T, Umezawa K, Horiuchi K, Hachisu M (2015) Plasma cholinesterase activity in Alzheimer’s disease. Neurodegener Dis 15:188–190CrossRefGoogle Scholar
  28. Kellam SG, Ensminger ME, Simon MB (1980) Mental health in first grade and teenage drug, alcohol, and cigarette use. Drug Alcohol Depend 5:273–304CrossRefGoogle Scholar
  29. Koob GF, Sanna PP, Bloom FE (1998) Neuroscience of addiction. Neuron 21:467–476CrossRefGoogle Scholar
  30. Lahiri DK, Nurnberger JI (1991) A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19:5444CrossRefGoogle Scholar
  31. Lima JK, Leite N, Turek LV, Souza RLR, da Silva Timossi L, Osiecki ACV, Osiecki R, Furtado-Alle L (2013) 1914G variant of BCHE gene associated with enzyme activity, obesity and triglyceride levels. Gene 532:24–26CrossRefGoogle Scholar
  32. Lockridge O (2015) Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther 148:34–46CrossRefGoogle Scholar
  33. Lockridge O, Norgren RB Jr, Johnson RC, Blake TA (2016) Naturally occurring genetic variants of human acetylcholinesterase and butyrylcholinesterase and their potential impact on the risk of toxicity from cholinesterase inhibitors. Chem Res Toxicol 29(9):1381–1392CrossRefGoogle Scholar
  34. Loewenstein-Lichtenstein Y, Schwarz M, Glick D, Nørgaard-Pedersen B, Zakut H, Soreq H (1995) Genetic predisposition to adverse consequences of anti-cholinesterases in “atypical” BCHE carriers. Nat Med 1:1082–1085CrossRefGoogle Scholar
  35. Mathew RJ, Hsu LL, Semchuk KM, Claghorn JL (1980) Acetylcholinesterase and pseudocholinesterase activities in anxiety. Am J Psychiatry 137:1118–1120CrossRefGoogle Scholar
  36. Mathew RJ, Ho BT, Khan MM, Perales C, Weinman ML, Claghorn JL (1982) True and pseudo cholinesterases in depression. Am J Psychiatry 139:125–127CrossRefGoogle Scholar
  37. Meyer MR (2013) The genetics of drugs of abuse metabolism. In: Miller PM (ed) Biological research on addiction. Academic Press, San Diego, pp 533–540CrossRefGoogle Scholar
  38. Modai I, Schwartz B, Aizenberg D (1987) Serum pseudocholinesterase in psychiatric patients. Biol Psychiatry 22:1238–1242CrossRefGoogle Scholar
  39. Mushtaq G, Khan JA, Kumosani TA, Kamal MA (2015) Alzheimer’s disease and type 2 diabetes via chronic inflammatory mechanisms. Saudi J Biol Sci 22:4–13CrossRefGoogle Scholar
  40. Negrão AB, Pereira AC, Guindalini C, Santos HC, Messas GP, Laranjeira R, Vallada H (2013) Butyrylcholinesterase genetic variants: association with cocaine dependence and related phenotypes. PLoS One 8:e80505CrossRefGoogle Scholar
  41. Nestler EJ (2013) Cellular basis of memory for addiction. Dialogues Clin Neurosci 15:431–443PubMedPubMedCentralGoogle Scholar
  42. Nordberg A, Ballard C, Bullock R, Darreh-Shori T, Somogyi M (2013) A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease. Prim Care Companion CNS Disord 15(2).   https://doi.org/10.4088/PCC.12r01412
  43. Oguri M, Kato K, Yokoi K, Yoshida T, Watanabe S, Metoki N, Yoshida H, Satoh K, Aoyagi Y, Tanaka M, Nozawa Y, Yamada Y (2009) Association of a polymorphism of BCHE with ischemic stroke in Japanese individuals with chronic kidney disease. Mol Med Rep 2:779–785PubMedGoogle Scholar
  44. Owen JA, Nakatsu K (1983) Diacetylmorphine (heroin) hydrolases in human blood. Can J Physiol Pharmacol 61:870–875CrossRefGoogle Scholar
  45. Pleva L, Kovarova P, Faldynova L, Plevova P, Hilscherova S, Zapletalova J, Kusnierova P, Kukla P (2015) The rs1803274 polymorphism of the BCHE gene is associated with an increased risk of coronary in-stent restenosis. BMC Cardiovasc Disord 15:135CrossRefGoogle Scholar
  46. Primo-Parmo SL, Bartels CF, Wiersema B, van der Spek AF, Innis JW, La Du BN (1996) Characterization of 12 silent alleles of the human butyrylcholinesterase (BCHE) gene. Am J Hum Genet 58:52–64PubMedPubMedCentralGoogle Scholar
  47. Reid GA, Darvesh S (2015) Butyrylcholinesterase-knockout reduces brain deposition of fibrillar β-amyloid in an Alzheimer mouse model. Neuroscience 298:424–435CrossRefGoogle Scholar
  48. Salmon AY, Goren Z, Avissar Y, Soreq H (1999) Human erythrocyte but not brain acetylcholinesterase hydrolyses heroin to morphine. Clin Exp Pharmacol Physiol 26:596–600CrossRefGoogle Scholar
  49. Shields KA, Lewis J (2018) The identification of butyrycholinesterase (BCHE) polymorphisms in a small Australian Defence force cohort. http://www.dsto.defence.gov.au/corporate/reports/DSTO-TR-2503.pdf. Accessed 28 July 2018
  50. Simchovitz A, Heneka MT, Soreq H (2017) Personalized genetics of the cholinergic blockade of neuroinflammation. J Neurochem 142[Suppl 2]:178–171CrossRefGoogle Scholar
  51. Tangvarasittichai S, Pongthaisong S, Meemark S, Tangvarasittichai O (2015) Abdominal obesity associated with elevated serum Butyrylcholinesterase activity, insulin resistance and reduced high density lipoprotein-cholesterol levels. Indian J Clin Biochem 30:275–280CrossRefGoogle Scholar
  52. UNODC (United Nations Office on Drugs and Crime) (2013) Drugs use in Pakistan. https://www.unodc.org/documents/pakistan/Survey_Report_Final_2013.pdf. Accessed 28 July 2018
  53. UNODC (United Nations Office on Drugs and Crime) (2016) World drug report 2016—world. https://reliefweb.int/report/world/unodc-world-drug-report-2016. Accessed 28 July 2018
  54. Valle A, O’Connor DT, Taylor P, Zhu G, Montgomery GW, Slagboom PE, Martin NG, Whitfield JB (2006) Butyrylcholinesterase: association with the metabolic syndrome and identification of 2 gene loci affecting activity. Clin Chem 52:1014–1020CrossRefGoogle Scholar
  55. Wang J-C, Kapoor M, Goate AM (2012) The genetics of substance dependence. Annu Rev Genomics Hum Genet 13:241–261.  https://doi.org/10.1146/annurev-genom-090711-163844 CrossRefPubMedPubMedCentralGoogle Scholar
  56. Worek F, Mast U, Kiderlen D, Diepold C, Eyer P (1999) Improved determination of acetylcholinesterase activity in human whole blood. Clin Chim Acta 288:73–90CrossRefGoogle Scholar
  57. Ye S, Humphries S, Green F (1992) Allele specific amplification by tetra-primer PCR. Nucleic Acids Res 20:1152CrossRefGoogle Scholar
  58. Ye T, Nightingale BN, Burns JC, Sullivan DR, Stewart PM (2003) Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. Clin Chem 49:1297–1308CrossRefGoogle Scholar
  59. Zaman M, Razzaq S, Hassan R, Qureshi J, Ijaz H, Hanif M, Rahman Chughtai F (2015) Drug abuse among the students. Pakistan J Pharmaceutical Res 1(1)41–47Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Biosciences, Functional Proteomics and Genomics LabCOMSATS University IslamabadIslamabadPakistan

Personalised recommendations